Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 27Terminated 11Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1

Interventions

pembrolizumab 84Specimen Handling 79Carboplatin 74Magnetic Resonance Spectroscopy 71Biopsy 58Nivolumab 55Cisplatin 55Paclitaxel 46Cyclophosphamide 44durvalumab 37Radiotherapy 36Radiation 35Rituximab 34olaparib 33Etoposide 33Dexamethasone 33Ipilimumab 30Gemcitabine 30Lenalidomide 28Taxes 27Pemetrexed 27Doxorubicin 27Docetaxel 27Bevacizumab 24Prednisone 23Cytarabine 23X-Rays 22Trastuzumab 21cabozantinib 20Disulfides 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Has results × binimetinib × Clear all
NCT04439344 2026-05-07

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
53 enrolled 10 charts
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡